In the present study, we evaluated the efficacy of monotherapy with Gal-3C, which is an N-terminally truncated form of galectin-3, and Gal-3C in a combination therapy with Bor in a NOD/SCID mouse model harboring human MM. The gene discussed is LGALS3; the disease is Miyoshi myopathy.